📈 FDA's loosened approval bar creates markets — capital floods the biotech complex

Friedberg equities 43% · n=123 · E80 (2022-05-13) · explicit_prediction · strength 2 ▶ 29:08 REVERSAL

“roughly one third of public biotech stocks are trading below cash. ... But because the capital markets are gone now for them, or the assumption is, hey, there's not going to be any capital left”

Friedberg equities 43% · n=123 · E59 (2021-12-17) · explicit_prediction · strength 2 ▶ 1:09:02 SUPPORT

“they really kind of struggled for years to find the right footing of what's the right business model and the right product and the FDA kind of struggled with approving this stuff. And then boom, COVID hit. ... I think there's now a few, a handful of these RNA interference products that have been approved by the FDA. And we're now starting to see many more of these cancer and immunotherapy drugs start to get approved as RNA therapies.”

Friedberg equities 43% · n=123 · E35 (2021-06-13) · explicit_prediction · strength 2 ▶ 23:27 SUPPORT · horizon 24mo

“Companies are going to rush in, they're going to try and get 10 things approved. Everyone's going to be taking an Alzheimer's drug in a couple of years because there's going to be so many available on the market. And none of them may actually be curing Alzheimer's.”

Chamath equities 42% · n=163 · E35 (2021-06-13) · explicit_prediction · strength 3 ▶ 20:55 SUPPORT

“they applied an extremely aggressive free market approach to a market that has been completely bereft of solutions. ... And so if you can create a hundred billion dollar market overnight, I think it stands to reason that a lot of people will look at the increase in Biogen's market cap and the profits that Biogen can make over the next 10 or 15 years and say, I will attack that and do that cheaper, faster, better. It happens in every other market.”

Sacks equities 44% · n=96 · E35 (2021-06-13) · sentiment · strength 2 ▶ 17:08 SUPPORT

“But going to the sort of larger issue of FDA approval, I would make it a little bit easier to get drugs approved. I mean, look, I think that double-blind test is the gold standard. If the drug clearly doesn't work, you don't approve it. But this is a case where the evidence is a little bit inconclusive.”